The types of hepatic myofibroblasts contributing to liver fibrosis of different etiologies

Jun Xu, Xiao Liu, Yukinori Koyama, Ping Wang, Tian Lan, In-Gyu Kim, In H. Kim, Hsiao-Yen Ma and Tatiana Kisseleva*

School of Medicine, University of California at San Diego, La Jolla, CA, USA

Liver fibrosis results from dysregulation of normal wound healing, inflammation, activation of myofibroblasts, and deposition of extracellular matrix (ECM). Chronic liver injury causes death of hepatocytes and formation of apoptotic bodies, which in turn, release factors that recruit inflammatory cells (neutrophils, monocytes, macrophages, and lymphocytes) to the injured liver. Hepatic macrophages (Kupffer cells) produce TGFβ1 and other inflammatory cytokines that activate Collagen Type I producing myofibroblasts, which are not present in the normal liver. Secretion of TGFβ1 and activation of myofibroblasts play a critical role in the pathogenesis of liver fibrosis of different etiologies. Although the composition of fibrogenic myofibroblasts varies dependent on etiology of liver injury, liver resident hepatic stellate cells and portal fibroblasts are the major source of myofibroblasts in fibrotic liver in both experimental models of liver fibrosis and in patients with liver disease. Several studies have demonstrated that hepatic fibrosis can reverse upon cessation of liver injury. Regression of liver fibrosis is accompanied by the disappearance of fibrogenic myofibroblasts followed by resorption of the fibrous scar. Myofibroblasts either apoptose or inactivate into a quiescent-like state (e.g., stop collagen production and partially restore expression of lipogenic genes). Resolution of liver fibrosis is associated with recruitment of macrophages that secrete matrix-degrading enzymes (matrix metalloproteinase, collagenases) and are responsible for fibrosis resolution. However, prolonged/repeated liver injury may cause irreversible crosslinking of ECM and formation of uncleavable collagen fibers. Advanced fibrosis progresses to cirrhosis and hepatocellular carcinoma. The current review will summarize the role and contribution of different cell types to populations of fibrogenic myofibroblasts in fibrotic liver.

Keywords: liver fibrosis, myofibroblasts, hepatic stellate cells, portal fibroblast, fibrocyte, carbon tetrachloride

INTRODUCTION
PATHOGENESIS OF LIVER FIBROSIS

Hepatic fibrosis is the outcome of many chronic liver diseases, including cholestatic liver diseases [primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), and secondary biliary cirrhosis (SBC)], and hepatotoxic liver diseases [hepatitis B virus (HBV), hepatitis C virus (HCV), alcoholic liver disease (ALD), and non-alcoholic steatohepatitis (NASH); Bataller and Brenner, 2005]. It is characterized by extensive deposition of extracellular matrix (ECM), including collagen Type I (Bataller and Brenner, 2005; Kisseleva and Brenner, 2007; Kisseleva and Brenner, 2008a,b, 2011). Hepatic fibrosis is caused by deregulation of physiological wound healing, and results in excessive production of ECM, mostly collagen type I, and scar formation. Activation of collagen producing myofibroblasts is critical for the pathogenesis of liver fibrosis (Bataller and Brenner, 2005; Kisseleva and Brenner, 2008b). Studies of animal models of liver fibrosis and patient material have demonstrated that activation of hepatic myofibroblasts plays a critical role in development of liver fibrosis. Increased number of myofibroblasts correlates with the severity of liver fibrosis in patients (Brenner et al., 2012). Therefore, myofibroblasts became an attractive target for anti-fibrotic therapy aimed to eliminate the source of activated hepatic myofibroblasts (Kisseleva et al., 2012; Liu et al., 2013). Myofibroblasts upregulate expression of α smooth muscle actin (α-SMA), non-muscle myosin, fibronectin, and exhibit stellate-like morphology. Myofibroblasts produce and secrete Collagen type I, the main component of the fibrous scar, and therefore, serve as a major source of ECM (Eyden, 2008; Watsky et al., 2010; Brenner et al., 2012). Although all myofibroblasts share common characteristics (such as expression of Col1α1, α-SMA, TGFβRII, TIMP1, PAI-1, activin, vimentin, fibropectin, activation of TGFβ1 signaling pathway), myofibroblasts may originate from distinct cellular sources, and the composition of myofibroblast population may vary dependent on the etiology of liver fibrosis. Identification of the cellular source(s) of fibrogenic myofibroblasts provides an invaluable insight into the pathophysiology of fibrogenic liver injury of different etiologies. Based on extensive studies, three cellular populations mainly contribute to hepatic myofibroblasts

Abbreviations: α-SMA, α-smooth muscle actin; αHSCs, activated HSCs; BDL, bile duct ligation; BM, bone marrow; CCl4; carbon tetrachloride; ECM, extracellular matrix; EMT, epithelial-to-mesenchymal transition; HCC, hepatic cellular carcinoma; HSCs, hepatic stellate cells; iHSCs, inactivated HSCs; KC, Kupffer cells; LPS, lipopolysaccharide; PF, Portal fibroblast, qHSCs, quiescent HSCs.
in response to chronic liver injury: hepatic stellate cells (HSCs; Kisseleva and Brenner, 2006, 2007), portal fibroblasts (PFs; Dra- noff and Wells, 2010), and bone marrow (BM)-derived collagen producing cells (fibrocytes; Kisseleva et al., 2006; Scholten et al., 2011; Iwaisako et al., 2012; Kisseleva and Brenner, 2012). Activated HSCs (αHSCs) are the major source of myofibroblasts in chronic toxic liver injury (HBV, HCV infection, ALD, and NAFLD). PFs were implicated in injury caused by cholestatic liver injury (primary and secondary biliary fibrosis; Bataller and Brenner, 2005). The role of fibrocytes in liver fibrosis remains unresolved. Recruitment of BM-derived fibrocytes into the injured liver was observed in animal models of both toxic and cholestatic liver fibrosis. However, contribution of fibrocytes to collagen producing myofibroblasts remains controversial. Identification of the origin of myofibroblasts plays a critical role in understanding the pathogenesis of liver fibrosis.

CELL FATE MAPPING OF HEPATIC MYOFIBROBLASTS

Exploitation of Cre-LoxP systems in mice provided new opportunities for cell fate mapping and lineage tracing of myofibroblasts of different origins (Gilbertson, 2003; Kisseleva et al., 2012). This technique is based on cell-specific expression of Cre recombinase (overexpressed under cell/lineage-specific promoter) in mice. Upon crossing of Cre-expressing mice with reporter mice, reporter is knocked into Rosa26 locus, specific lineages of myofibroblasts and their progeny can be visualized and traced by expression of a fluorescent protein such as GFP or YFP.

ORIGIN OF HEPATIC MYOFIBROBLASTS

Several sources of hepatic myofibroblasts have been identified (Kalluri and Neilson, 2003; Kisseleva and Brenner, 2006; Fallowfield et al., 2007; Gomperts and Strieter, 2007). HSCs and PFs are the resident mesenchymal cells (Asahina et al., 2009), they activate and proliferate in response to injury, and are believed to be the major source of myofibroblasts in fibrotic liver (Bataller and Brenner, 2005; Kisseleva et al., 2006, 2011; Parola et al., 2008; Roderfeld et al., 2009; Scholten et al., 2011). BM-derived fibrocytes and mesenchymal progenitor cells are recruited to the injured liver and become myofibroblasts (Bucala et al., 1994; Russo et al., 2006). Hepatic epithelial cells may undergo a transition into mesenchymal cells to contribute to the pathogenesis of liver fibrosis.

HEPATIC STELLATE CELLS

Hepatic stellate cells are liver resident cells that originate from embryonic mesenchyme, and in adult healthy liver constitute approximately 10% of total liver cells. Under physiological conditions, HSCs exhibit a quiescent phenotype and serve as a major storage of Vitamin A. Quiescent HSCs (qHSCs) are located in the space of Disse (designated space between hepatocytes and sinusoidal endothelial cells), store retinoids in lipid droplets, and express desmin, neural markers, such as glial fibrillary associated protein (GFAP), synaptophasin, synemin, and nerve growth factor receptor p75 (Geerts, 2001; Bataller and Brenner, 2005). In addition, Nr1d2, Adipor1, Adipf, Dbp, Prei4, and Foxj1 were identified as unique markers associated with HSC quiescent phenotype (Liu et al., 2013). In response to fibrogenic liver injury and release of TGFβ1, qHSCs rapidly undergo activation. They downregulate Vitamin A-containing lipid droplets and neural markers, and differentiate into collagen Type I and αSMA-expressing αHSCs/myofibroblasts (Bataller and Brenner, 2005; Forbes and Parola, 2011). They also upregulate production of matrix metalloproteinases MMPs, especially MMP13, and their inhibitors TIMPs (Uchinami et al., 2006). Activation of HSCs is triggered mostly by increased hepatic levels of profibrogenic TGFβ1. In addition, PDGF, FGF, and CTGF also induce HSC activation (Pinzani and Marra, 2001; Reif et al., 2003; Hao et al., 2013). Recent studies have demonstrated that IL-6, leptin, and IL-17A can also trigger HSC activation (Bethanis and Theocharis, 2006; Michalopoulos, 2007; Meng et al., 2012). In addition αHSCs upregulate Crf1f, Sppl, Lox, Loxl2, IL-17Ra, Fosil1, and Forl1, genes that are uniquely associated with αHSC phenotype (Liu et al., 2013).

**Transgenic mice to study HSCs**

Reporter Collagen-α1(I)-GFP (Col-GFP) mice (Yata et al., 2003) are widely used to study activation of myofibroblasts in many types of organ fibrosis. Expression of GFP driven by Collagen-α1(I) promoter/enhancer (Yata et al., 2003) in these mice closely correlates with expression of Collagen Type I protein (Magness and Brenner, 1999; Magness et al., 2004), which is a major component of the fibrous scar (Bataller et al., 2003). These mice have been extensively characterized and have become a standard tool to visualize myofibroblasts contributing to fibrosis in liver, lungs, kidneys, and skin (Brenner et al., 1989; Stefanovic et al., 1997, 2000, 2002, 2005; Stefanovic and Brenner, 2003; Kisseleva et al., 2006, 2011; De Minicis et al., 2007; Lin et al., 2008; Taura et al., 2008, 2010; Österreicher et al., 2011; Inokuchi et al., 2011; Parsons et al., 2011; Scholten et al., 2011; Meng et al., 2012; Meurer et al., 2013). Using the Col-GFP mice we have recently demonstrated that αHSCs [isolated by flow cytometry as GFP+ cells (Friedman et al., 1985; Bataller and Brenner, 2005; Seki et al., 2007)] comprise >92% of myofibroblasts in response to CCl4 (Kisseleva et al., 2012). Furthermore, significant progress has recently been made in the understanding of HSC biology based on HSC cell fate mapping. For this purpose, αHSCs were irreversibly labeled in CCl4-injured mice using Col1α1-Cre mice, Col1α2-Cre mice, and inducible Col1α1-ERCre mice. This technique allowed not only to trace and isolate αHSCs from a pool of non-parenchymal cells using flow cytometry-based cell sorting technique, but also to determine their cellular fate during regression of liver fibrosis (Kisseleva and Brenner, 2008a; Troeger et al., 2012). Hence, utilization of Cre expressing mice, in which Cre expression is driven by collagen Type I promoter, results in labeling of all hepatic myofibroblasts. Therefore, several successful attempts were made to generate HSC-specific Cre mice. Thus, vimentin-ERCre mice have recently been reported to label αHSCs (Troeger et al., 2012), while lecithin-retinol acyltransferase (Lrat)-ERCre mice induce tamoxifen-inducible Cre-LoxP recombination in HSCs independent of the status of their activation (Mederacke et al., 2013). Off note, previous attempts at HSC fate tracing have utilized hGFAP-Cre mice, however this yielded rather controversial results, since hepatic Cre-LoxP recombination in these mice generated three different phenotypes: recombination
in HSCs (Kisseleva and Brenner, 2008a; Krizhanovsky et al., 2008; Lujambio et al., 2013), in cholangiocytes (Mederacke et al., 2013), or in both HSCs and cholangiocytes (Yang et al., 2008).

Reversibility of liver fibrosis

Many studies have clearly demonstrated that hepatic fibrosis is reversible in patients (e.g., HBV, HCV, biliary obstruction, or alcohol) and in experimental rodent models (alcohol feeding, CCl4, or bile duct ligation; Kisseleva and Brenner, 2011). Upon removal of the etiological source of the chronic injury, regression of liver fibrosis is associated with decreased cytokines and ECM production, increased collagenase activity, disappearance of myofibroblast population and dissolution of the fibrous scar (Iredale et al., 1998; Bataller and Brenner, 2005). Only recently has the fate of these myofibroblasts been revealed. The previous concept was that the myofibroblasts undergo apoptosis on the basis of documented senescence during reversal of fibrosis. We (Kisseleva et al., 2012) and subsequently others (Troeger et al., 2012) have used genetic marking to demonstrate an alternative pathway in which myofibroblasts revert to a quiescent-like phenotype in CCl4-induced liver injury and experimental ALD. Genetic marking of myofibroblasts enabled the quantitative mapping of the fate of these cells in experimental models of fibrosis and its reversal.

Inactivation of HSCs

The mechanism of HSC activation is well understood, but very little is known about HSC biology in the post-fibrosis phase. Using the Cre-LoxP-based genetic labeling of myofibroblasts, the fate of HSCs/myofibroblasts during recovery from CCl4-induced liver fibrosis has been elucidated, and it has been demonstrated that half of myofibroblasts undergo senescence (Krizhanovsky et al., 2008) and apoptosis (Iredale et al., 1998; Iredale, 2001), while half escape apoptosis during regression of liver fibrosis, downregulate fibrogenic genes and acquire a phenotype similar to, but distinct from, qHSCs (Kisseleva et al., 2012). In particularly, iHSCs more rapidly reactivate into myofibroblasts in response to fibrogenic stimuli and more effectively contribute to liver fibrosis. Inactivation of HSCs is associated with re-expression of lipogenic genes PPAR-γ, Insig1, and CREBP (She et al., 2005). Our findings in mice support the in vitro studies demonstrating the importance of PPAR-γ for the maintenance of quiescent phenotype (qHSCs; Gaca et al., 2003; She et al., 2005; Tsukamoto, 2005a,b; Wells, 2008). Following regression of liver fibrosis, HSCs restore their cellular mass and Vitamin A storage.

It remains unclear why some aHSCs apoptose during regression of liver fibrosis, and some aHSC inactivate (Kisseleva et al., 2012). Gene expression profiling of HSCs have demonstrated that those HSCs that survive and inactivate strongly upregulate Hsp1a/b heat shock proteins. Hsp1a/b proteins belong to Hsp70 family of heat shock proteins. Hsp1a/b proteins are expressed only in certain cell types in response to stress. We have demonstrated that Hsp1a/b knockout HSCs are more susceptible to glycolysis or TNFα-induced apoptosis. In addition, regression of liver fibrosis in Hsp1a/b−/− is accompanied by massive apoptosis of aHSCs, suggesting that these two proteins may be involved in inactivation of HSCs (Kisseleva et al., 2012).

Epigenetic regulation

Understanding the mechanisms of HSC inactivation during regression of liver fibrosis is critical for finding new targets for anti-fibrotic therapy. Inactivation of HSCs is most likely regulated at an epigenetic level (versus genetic mutations; Mann et al., 2010; Tsukamoto et al., 2011). Epigenetics are heritable changes in gene function that occur without a change in the DNA sequence (Pepke et al., 2009). These changes, including nucleosome dynamics and histone modifications, cause structural alterations in the chromatin structure, and greatly affect gene expression. Post-translational modifications of the core histone subunits of nucleosomes are a fundamental mechanism by which the transcriptional activity of an associated gene locus can be regulated by methylation, acetylation, and phosphorylation (Henikoff, 2008; Park, 2009; Heinz and Glass, 2012). DNA methylation of genes expressed in qHSCs probably contributes to the maintenance of the quiescent phenotype. Upon activation, HSCs express DNA methyl-binding proteins (MeCP2) that promote silencing of antifibrogenic genes, such as IκB-α or PPAR-γ, and increase the expression of histone methyl transferase, leading in turn to enhanced transcription of collagen, TIMP-1, and TGF-β. PPARγ expression is associated with the adipogenic features of qHSC and must be silenced for the cell to activate into myofibroblasts (Hazra et al., 2004; She et al., 2005; Tsukamoto et al., 2012; Yang et al., 2012). A novel multi-step epigenetic network that controls activation of HSCs in the injured liver has recently been described, and involves activation of MeCP2 that causes alterations at the H3K27 methylation sites and generates transcriptionally repressed chromatin structure in the PPARγ promoter (She et al., 2005; Mann et al., 2010). Consistently, overexpression of PPARγ in aHSCs/myofibroblasts in vitro results in reversion of HSC activation, and reacquisition of their adipogenic characteristics (Hazra et al., 2004; Jaster et al., 2005).

The origin of HSCs

Hepatic stellate cells are believed to originate from mesenchymal cells during embryogenesis and recovery from liver injury (Cassiman et al., 2002; Bataller and Brenner, 2005). However, several important questions regarding HSC biology remain unknown. For example, what is the half-life of HSCs? What cell type(s) give rise to HSCs during liver organogenesis and in the adult liver? Finally, what triggers HSC proliferation during activation of liver fibrosis? HSCs share characteristics of both neural cells (expression of astrocyte marker GFAP, nestin and p75Ntr; Geerts, 2001), and mesodermal cells (smooth muscle marker desmin, adipocyte characterization, and ability to transdifferentiate into myofibroblasts). Cell fate mapping of Wnt+ cells (using Wnt1-Cre mice x Rosa-flox-Stop-flox-YFP mice) have demonstrated that HSCs do not originate from neural crest precursors which derive to all astrocytes (Cassiman et al., 2006). In turn, using lineage tracing of MesP1+ cells Asahina et al. (2011) have demonstrated that HSCs and PFs originate from mesenchymal precursors. In response to injury HSCs proliferate and activate into myofibroblasts. Cell fate mapping of aHSCs [Collagen-a1(I)-Cre mice x Rosa-flox-Stop-flox-YFP mice] have revealed that upon cessation of liver injury aHSCs either apoptose or inactivate into a quiescent-like state (Kisseleva et al., 2012). Interestingly, along with inactivated HSCs,
which are genetically labeled and can be identified by YFP expression, we observed an emerging population of new HSCs without the “history” of collagen expression (Kisselева et al., 2012). New studies are required to identify the source of HSCs in adult liver.

**PORTAL FIBROBLASTS**

Portal fibroblasts reside underneath of the bile duct epithelium and are the major myofibroblast source in biliary cirrhosis, which is caused by biliary obstruction (Clouzeau-Girard et al., 2006; Dranoff and Wells, 2010). Biliary cirrhosis is characterized by dysregulated cholangiocyte proliferation and bile ductular enlargement (Jhandier et al., 2005). Although PFs are the first “responders” to liver injury caused by biliary obstruction (Wells et al., 2004), HSCs (and to lesser extend fibrocytes) also contribute to myofibroblast populations with the disease progression (Goddard et al., 1998).

**Definition of PFs**

Portal fibroblasts are a heterogeneous population and represent one of several fibroblast populations in the liver. The term “portal fibroblast” refers to any fibroblast in the portal region, and the term “portal myofibroblast” to any myofibroblast that originates in the portal area and is not derived from HSCs (Wells, 2014). Therefore, here we define aPFs as fibroblasts expressing fibulin 2, elastin, Thy1, interleukin 6, and the ectonucleotidase NTDPase 2, and do not express markers of stellate cells (Chapman and Eagles, 2007). There are other fibroblasts surrounding the central vein (second layer cells) and in the liver capsule (Blunchet and Wake, 1992; Chapman and Eagles, 2007), many of which are derived from a common mesothelial or submesothelial progenitor cell that also gives rise to HSCs (Asahina et al., 2011). These populations have not been well defined or studied, and little is known about their contribution to fibrosis, epithelial maintenance, and other functions essential to the health of the liver and bile ducts.

**Activation of PFs**

Under physiological conditions, PFs comprise a small population of cells that surround the portal vein to maintain integrity of the portal tract (Dranoff and Wells, 2010). Activated PFs (aPFs) are implicated in the pathogenesis of cholestatic liver injury (Desmouliere et al., 1997), in which they proliferate and differentiate into α-SMA-expressing myofibroblasts that synthesize ECM (Desmouliere et al., 1997; Yata et al., 2003; Dranoff and Wells, 2010). The contribution of aPFs to liver fibrosis of different etiologies is not well understood, mainly because of the difficulties involved with the isolation of PFs and myofibroblasts. The most widely used method of aPF isolation from rat liver is based on enzymatic digestion followed by size selection (Wen et al., 2012). Cell outgrowth from dissected bile segments is still used to isolate rat PFs (Uchio et al., 2002), and after 10–14 days in culture PFs undergo progressive myofibroblastic differentiation (Kruglov et al., 2002). Unfortunately, this technique has several disadvantages since it requires multiple passaging and prolonged culturing which change the original phenotype of the cells (Dranoff and Wells, 2010). A more physiological method of studying PFs is precision-cut liver slices (PCLS), designed to maintain cell–cell and cell–matrix interactions and mimic the natural microenvironment of PFs, but this does not enable the study of purified populations of PFs. Only a few markers are available to identify PFs in the myofibroblast population, including gremlin, Thy1 (Knittel et al., 1999; Dudas et al., 2007; Yovchev et al., 2009), fibulin 2 (Knittel et al., 1999), IL-6, elastin (Goodpaster et al., 2008), the ecto-AT-Pase nucleoside triphosphate diphosphohydrolase-2 (NTPD2; Dranoff et al., 2002), and colllin 1 (Bosselet et al., 2010). aPFs may also upregulate intermediate filament vimentin, the collagen receptor DDR2, and the calcium-binding protein S100A4 (Fsp1), and exhibit reactivity to the monoclonal antibody TE-7. In addition, the lack of desmin, cytoglobin, β2-macroglobulin, and Hand2, GFAP, p75NGr, and Vitamin A distinguishes PFs from HSCs (Bataller and Brenner, 2005; Dranoff and Wells, 2010; Fausther and Dranoff, 2011). Identification of additional PF markers will advance our understanding of the pathogenesis of liver fibrosis.

**Specific characteristics of aPFs**

Two models of cholestatic liver injury are routinely used to study activation of PFs in mice. Bile duct ligation is caused by surgical obstruction of the common bile duct and mimics cholestatic liver disease in patients. Mice deficient in the canalicular phospholipid flippase (Mdr2/Abcb4−/− mice) spontaneously develop liver injury (PSC; Shimamura et al., 2008), (Fichtner-Feigl et al., 2006; Jinnin et al., 2006; Fickert et al., 2009; Baghdasaryan et al., 2010; Mair et al., 2010; McHedlidze et al., 2013), which resembles PSC and most closely mimics MDR3 deficiency in patients (Pope et al., 2005) which ranges from familial intrahepatic cholestasis to adult liver cirrhosis. The pathogenesis of liver injury in Mdr2−/− mice is characterized by disruption of tight junctions and basement membranes of bile ducts, bile leakage into the portal tract, and formation of perportal biliary fibrosis (Jinnin et al., 2006; McHedlidze et al., 2013). aPFs were proposed to contribute to ECM deposition in Mdr2−/− mice and in response to bile duct ligation (Jinnin et al., 2006; Fickert et al., 2009). In the case of cholestatic liver injury aPFs respond rapidly to increasing levels of TGF-β1 (Liu et al., 2003) by upregulation of Col-α1(I), α-SMA, TIMP1, TGF-β2 (Wells et al., 2004), PAI-1, elastin (Dranoff and Wells, 2010), fibronectin (Knittel et al., 1999; Ji et al., 2012), and of CD73 ecto-enzyme (Li et al., 2007; Fausther et al., 2012; Ji et al., 2012), and differentiate into collagen producing myofibroblasts. BDL-aPFs also secrete TGF-β1 and TGF-β2 (Wells et al., 2004). FGF-2 facilitates activation of PFs as well (Venkataraman et al., 1999). Binding of FGF-2 to its tyrosine kinase receptors FGFRs, and subsequent activation of Ras-MEK-Erk1/2 signaling causes rapid proliferation and migration of aPFs (Itoh and Ohta, 2013). Proliferation and activation of aPFs was shown to be blocked by Curcumin, a non-steroidal yellow pigment found in rhizomes of the perennial herb Curcuma longa, which blocks ERK1/2 phosphorylation in aPFs, and thus has a potential to reduce cholestasis-induced fibrogenesis (Baghdasaryan et al., 2010). aPFs are believed to be the “first responders” to cholestatic liver injury which contribute to a significant number of collagen producing myofibroblasts. aPFs begin to proliferate immediately after bile duct ligation giving rise to a population of desmin Vitamin A− α-SMA+ myofibroblasts adjacent to proliferating bile ducts and...
connective tissue stroma (Wells, 2014). Activation of PFs proceeds activation and proliferation of HSCs, suggesting that activation of HSCs is secondary to PFs in response to cholestatic liver injury (Tuchweber et al., 1996; Desmouliere et al., 1997). In addition, PFs play a role in maintenance of the peribiliary stem cell niche, regulation of cholangiocyte proliferation, and deposition of specific matrix proteins, such as elastin and other components of microfibrils, providing stability to ducts and the vasculature under conditions of increased ductal pressure (Wells, 2014). Recent studies have also proposed that HSCs and PFs occupy different niches which yield myofibroblasts with specialized functions dependent on the etiology of liver injury. If the HSC niche is activated in response to hepatotoxic damage and hypoxia to produce myofibroblasts that mediate hepatocellular healing, then the portal fibroblast niche is activated by the ductular reaction to produce PF–derived myofibroblasts that regulate scar formation (Lemoine et al., 2013; Wells, 2014).

**Origin of portal fibroblast**

Recent studies have suggested that during embryonic development PFs, HSCs and vascular smooth muscle cells (VSMC) originate from mesenchymal precursors of septum transversum (Suzuki et al., 2008; Asahina et al., 2009). Lineage tracing of precursor cells expressing mésodermal marker, MesP1<sup>GFP</sup>, provides evidence that septum transversum originates from mesoderm (Asahina et al., 2011). At day 9.5 (E9.5) of mouse embryogenesis, when the hepatic bile duct system and sinusoid start to form, septum transversum is invaded by foregut endoderm. At E12.5, the perihepatic membrane mesothelial cells and submesothelial cells give rise to the mesenchymal cell precursors which invade into the liver mesenchyme (Asahina et al., 2011; Rinkevich et al., 2012). Several cell markers of these mesenchymal cell precursors have been identified, including Mesothelin, Desmin, p75NTR, Wt1, and ALCAM. These mesenchymal precursors interact with endodermal hepatoblasts to induce the differentiation of hepatic parenchyma. It remains unclear at which time point and specific stage of embryonic development PF and HSC precursors diverge from each other and retain expression of cell specific markers throughout adulthood distinguishing these two cell types from each other. One explanation which has evolved is that positioning during hepatic lobule formation may designate functional specialization leading to divergence of PFs from HSCs. In concordance, fetal PFs secrete BMPs, Jagged1, and Hedgehog ligands to induce signaling critical for differentiation of hepatoblasts into cholangiocytes during bile canaliculi and lumen formation (Dranoff and Wells, 2010; Fabris and Strazzabosco, 2011), while fetal HSCs were implicated in supporting proliferation of hepatoblasts by producing HGF, pleiotrophin and FGF10 (Asahina et al., 2002; Berg et al., 2007).

**FIBROCYTES**

**Bone marrow derived collagen producing Fibrocytes**

Fibrocytes were first described by Bucala et al. (1994), Bucala (2008), and Grieb et al. (2011) and are defined by the simultaneous expression of CD45 and collagen type I. Fibrocytes possess dual characteristics of fibroblasts (expression of collagen type I, fibronectin, and vimentin) and hematopoietic cells (CD45, CD34, MHCII, CD11b, Gr1, Ly6c, CD54, CD80, CD86, CCR2, CCR1, CCR7, CCR5; Abe et al., 2001; Quan et al., 2004). Under physiological conditions, fibrocytes have a spindle-like shape. In response to injury (including liver injury), or stimulation by TGF-β, fibrocytes downregulate expression of hematopoietic markers and rapidly differentiate into α-SMA<sup>+</sup> myofibroblasts (Quan et al., 2004; Quan and Bucala, 2007). Due to their ability to give rise to fibrogenic myofibroblasts, fibrocytes were implicated in the pathogenesis of skin, lung, kidney, and liver fibrosis (Phillips et al., 2004; Moore et al., 2005, 2006; Kisseleva et al., 2006; Sakai et al., 2006; Ishida et al., 2007; Strieter et al., 2007; Wada et al., 2007; Lin et al., 2008; Grieb et al., 2011).

**Approach to identify and study fibrocytes in mice**

We have developed a new functional method to distinguish fibrocytes from liver resident fibrogenic myofibroblasts (Kisseleva et al., 2006; Higashiyama et al., 2009), or other BM-derived cells (Scholten et al., 2010; Kisseleva et al., 2011). Based on the ability of a collagen-α1(I)-GFP transgene (Yata et al., 2003) to drive GFP expression specifically in fibrocytes, but not other cells of the hematopoietic system [such as activated macrophages (Pilling et al., 2006), fibrocyte-specific BM chimeric mice Col-GFP→wt mice (generated by transplantation of Col-GFP BM into lethally irradiated wild type recipient mice) became a useful tool to study fibrocyte biology. Liver injury causes rapid recruitment of BM-derived fibrocytes (Russo et al., 2006; Kallis and Forbes, 2009) to fibrotic livers of Col-GFP→wt mice. Using Col-GFP→wt mice, we have identified that fibrogenic liver injury activates several populations of fibrocytes, hepatic (Kisseleva et al., 2006), splenic (Kisseleva et al., 2011), and BM CD45<sup>+</sup>Col<sup>+</sup> fibrocytes (Brenner and Kisseleva, 2011; Scholten et al., 2011).

**Fibrocytes contribute to liver fibrosis**

CD45<sup>+</sup>Col<sup>+</sup> fibrocytes migrate to the injured liver in response to bile duct ligation (BDL, cholestatic injury) and comprise ≈4–6% of the collagen type I expressing cells (Kisseleva et al., 2006). Similarly, fibrocytes are recruited into CCl4-damaged liver (Figures 1A,B), where they can differentiate into α-SMA<sup>+</sup> myofibroblasts in vivo (Scholten et al., 2011), suggesting that fibrocyte recruitment to the liver is a universal mechanism in the pathogenesis of liver fibrosis. In support, a significant number of fibrocytes is recruited in Abcb4 knockout mice, a genetic model of spontaneous liver fibrosis. There was a significant flux of fibrocytes to the liver in these mice, such that fibrocytes contributed ≈50% to the liver myofibroblast population (Roderfeld et al., 2009). Although the mechanism of fibrocyte recruitment caused by this genetic deficiency is not completely understood, it demonstrates that fibrocytes have a strong potential to differentiate into myofibroblasts under specific circumstances. For example, adoptively transferred fibrocytes that differentiate into collagen producing cells when cultured on plastic, exacerbate pulmonary fibrosis in mice (Phillips et al., 2004). This phenomenon emphasizes fibrocyte plasticity, fibrogenic potential, and organ-specific differentiation.

**Migration of fibrocytes to fibrotic liver**

Development of liver fibrosis is mediated by increased secretion of biologically active TGF-β1, intestinal lipopolysaccharide (LPS) and pro-inflammatory chemokines CCL2, CCL7, CCL12,
FIGURE 1 | Pathogenesis of liver fibrosis. (A) Hepatic lobular structure under physiological conditions. Hepatic sinusoid, cholangiocytes and hepatocytes, endothelial cells, hepatic stellate cells (HSCs) and portal fibroblasts (PFs), and Kupffer cells (KCs) are the components of hepatic lobule. The bile duct, portal vein and hepatic artery form the portal triad. HSCs are located in the space between hepatocytes and sinusoidal endothelium, designated as the space of Disse. HSCs are considered as liver pericytes, they contain lipid droplets and serve as the major storage of vitamin A. KCs represent a population of hepatic macrophages. Only few fibrocytes are present in the healthy liver. (B) Changes in the hepatic lobule caused by chronic liver injury. In response to chronic liver injury, hepatocytes undergo apoptosis and release factors that recruit Kupffer cells, BM macrophages, and fibrocytes into the damaged liver. KCs, BM macrophages, and fibrocytes release TGFβ1, the most potent profibrogenic cytokine, which activates HSCs into collagen Type I expressing myofibroblasts. HSCs, PFs and, to a lesser extent fibrocytes, deposit extracellular matrix (ECM).
and CCL3, which are the ligands for chemokine receptors CCR2 and CCR1 on hepatic and BM-derived cells (Seki et al., 2009a,b). TGF-β1 triggers fibrocyte mobilization into fibrotic liver, suggesting that regulation of fibrocyte migration by TGF-β1 might be a general characteristic of fibrogenic injury of the liver and other parenchymal organs (Phillips et al., 2004; Balmelli et al., 2007; Hong et al., 2007). Moreover, recruitment of fibrocytes from the BM to the injured liver is regulated by CCR2 (Scholten et al., 2010), a chemokine receptor that is also required for fibrocyte migration into fibrotic lungs and kidneys (Phillips et al., 2004; Moore et al., 2005; Sakai et al., 2006; Balmelli et al., 2007; Hong et al., 2007; Ekert et al., 2011). Unlike lungs and kidneys (Phillips et al., 2004; Moore et al., 2005, 2006; Sakai et al., 2006; Ishida et al., 2007; Wada et al., 2007), recruitment of fibrocytes to fibrotic liver was shown to be dependent on CCR1 (Scholten et al., 2010), indicating that differential expression of chemokine receptors may determine an organ-specific migration of fibrocytes in response to fibrogenic injury.

**BM is the source of hepatic fibrocytes**

Studies using bone marrow transplantation (BMT) in mice have established that BM is the source of fibrocytes. Under physiological conditions fibrocytes are primary located in the BM (comprise 0.1% of mononuclear cells), but proliferate and transmigrate with the blood stream in response to injury (Quan et al., 2004). Fibrocytes have been isolated from fibrotic tissues, spleens and peripheral blood (Bucala et al., 1994; Quan et al., 2004; Scholten et al., 2011). BM-derived fibrocytes have a spindle-like shape, but in response to TGF-β1, they rapidly obtain a myofibroblast phenotype (Quan et al., 2004). These BM fibrocytes possess all classical characteristic of fibrocytes: expression of collagen, CD45, CD11b, CD34, Gr1, CD80, and CD86 (Quan et al., 2004; Bellini and Mattoli, 2007; Reilkoff et al., 2011). BM-derived fibrocytes migrate specifically into fibrotic liver when adoptively transferred into BDL mice (Scholten et al., 2011), supporting the notion that BM fibrocytes are a source of hepatic fibrocytes/myofibroblasts.

**Development of liver injury is accompanied by recruitment of fibrocytes to the spleen**

In addition to the injured organ, recruitment of CD45+Col+ fibrocytes to the spleen has been documented during development of liver (Kisseleva et al., 2006; Niedermeier et al., 2009) and kidney fibrosis (Sakai et al., 2006). Hepatotoxic injury (CCL4), TGF-β1, LPS, or infection with *Listeria monocytogenes* (Lm) triggers migration of fibrocytes from the BM to the spleen and liver (Kisseleva et al., 2011). Moreover, the spleen functions as a major reservoir of immature fibrocytes. Splenic CD45+Col+ fibrocytes express myeloid markers and resemble CD115+CD11b+ monocytes (Kisseleva et al., 2011). Migration of fibrocytes specifically to Lm-infected spleen and liver indicate their potential role in innate immunity. Although the biological significance of splenic fibrocytes is not understood, our recent study suggests that CD45+Col+ fibrocytes are capable of differentiating according to their microenvironment, giving rise to different subtypes of fibrocyte-like cells with distinct roles during tissue repair and fibrosis (Curnow et al., 2010). Consistent with this observation, splenic fibrocytes uniquely upregulate a variety of antimicrobial factors [myeloperoxidase, cathelicidin (mCRAMP), defensins: Kisseleva et al., 2011], and expression of MHC II (Scholten et al., 2011). Although splenic fibrocytes lack phagocytic activity, they have developed alternative mechanisms to combat infection. First, splenic fibrocytes confine bacterial spread at the site of infection by entrapment of bacteria in extracellular DNA-based structures (“DNA traps”; Kisseleva et al., 2011), a mechanism previously identified only in neutrophils, eosinophils, mast cells, and macrophages (Brinkmann et al., 2004; von Kockritz-Blickwede et al., 2008; Yousefi et al., 2008; Chow et al., 2010). Fibrocytes kill bacteria by secretion of cathelicidin into the DNA-based framework (Kisseleva et al., 2011). Second, upon migration to the spleen, fibrocytes strongly upregulate expression of MHC II (Scholten et al., 2011) and mediate adaptive immunity by presenting antigens to naïve T cells (Chesney et al., 1997; Balmelli et al., 2005) in vivo and in vitro (Kisseleva et al., 2011). Although the antimicrobial properties of fibrocytes are aimed at stopping infection (Brinkmann and Zychlinsky, 2007), release of nuclear DNA and lysosomal peptides into the extracellular space facilitates inflammation, and was shown to cause autoimmune vasculitis (Kessenbrock et al., 2009).

**EPITHELIAL MESENCHYMAL TRANSITION (EMT) AND LIVER FIBROSIS**

The origin of myofibroblasts from hepatic epithelial cells is controversial. Although several evidence indicated that, under prolonged *in vitro* culturing, hepatocytes and cholangiocytes upregulate myofibroblast marker aSMA and suppress epithelial cellular marker (Kisseleva and Brenner, 2008a; Choi and Diehl, 2009; Kalluri, 2009), the fate mapping-based studies have clearly demonstrated that hepatocytes and cholangiocytes, or their precursors do not undergo EMT in response to experimental models of liver fibrosis and do not give rise to myofibroblasts (Scholten et al., 2010; Chu et al., 2011; Österreicher et al., 2011). These studies have shown that genetic labeling of hepatocytes (using Albumin-Cre mice), cholangiocytes [using cytokeratin 19 (K-19)-Cre mice] and their precursors did not yield generation of myofibroblasts in vivo. Furthermore, expression of S100A4 (Fsp1), a marker which is associated with EMT progression, and widely used to detect cells undergoing EMT, has been found to be expressed not only by subsets of fibroblasts but also by myeloid cells, suggesting that the role of this protein in the pathogenesis of liver fibrosis has to be reevaluated.

**HUMAN LIVER DISEASES AND FIBROGENIC CELL POPULATIONS**

It is well established that liver myofibroblasts are the primary effector cells responsible for the extensive ECM accumulation and scar formation observed during hepatic fibrosis (Fausther et al., 2013). Liver myofibroblasts represent the critical targets for antifibrotic therapies, and therefore, it is important to determine the composition and contribution of distinct subsets of myofibroblasts to clinical and experimental liver fibrosis of different etiologies (Fausther et al., 2013). Based on the analysis of liver material from patients with advanced fibrosis and cirrhosis, three distinct mesenchymal myofibroblast-like liver cell subpopulations can be discerned: portal/septal myofibroblasts, interface myofibroblasts,
and perisinusoidally located aHSCs. Septal myofibroblasts share more characteristics with portal myofibroblasts than with HSCs perhaps suggesting their common descent (Cassiman et al., 2002). However, contribution of these subpopulations vary dependent on underlying etiology of liver fibrosis. Thus, primarily activation of HSCs with upregulation of α-SMA is observed in patients with viral hepatitis B and C (Giannelli and Antonaci, 2005; Friedman, 2008a,b). In addition, viral antigens and dsDNA are able to activate HSCs via CD4/CD8 lymphocyte mediated manner (Enzan et al., 1994; Muhanna et al., 2008). In cholestatic liver fibrosis, both aPFs and aHSCs contribute to the ECM deposition, and the major accumulation of collagen expressing cells have been observed around proliferating bile ducts (Goddard et al., 1998).

Recruitment of fibrocytes in patients with liver fibrosis has been documented. The number of circulating fibrocytes was shown to correlate with the severity of fibrosis induced by HCV (Bucala, 2008), lung fibrosis (Strieter et al., 2009) and Crohn’s disease (Sahebally et al., 2013), suggesting that fibrocytes may serve as a prognostic marker, and become a novel target for anti-fibrotic therapy in fibrosis. However, the function of fibrocytes in the liver is not well understood. Thus, fibrocytes were implicated to be a major source of collagen Type I producing cells in patients with nephrogenic systemic fibrosis (NSF; Cowper and Bucala, 2008; Galan et al., 2006). Meanwhile, recent reports suggest that fibrocyte function is not limited to ECM deposition, and fibrocytes also act to promote fibrosis via paracrine actions, such as secretion of growth factors, proteases, and matricellular proteins, which affect resident epithelial and mesenchymal cells towards pathologic remodeling (Kleaveland et al., 2014).

Although the data supporting the concept of EMT in adult patients with liver fibrosis has recently been critically questioned, there is evidence that EMT occurs during mammalian embryogenesis and cancerogenesis. It is quite possible that pediatric patients who are born with biliary atresia may retain a rudimentary mechanism by which bile ducts undergoing EMT may account for prominent bile ductular proliferation and fibrogenesis (Deng et al., 2011). Liver sections from patients with biliary atresia were evaluated to detect antigen for the BEG markers 4 and cytokeratin-7 (CK-7), proteins (fibroblast-specific protein 1, also known S100A4; the collagen chaperone heat shock protein 47, HSP47) characteristically expressed by cells undergoing EMT, as well as myofibroblast marker a-smooth muscle actin (a-SMA).

CONCLUSION
The composition of myofibroblasts varies dependent on the etiology of liver fibrosis. Hence, liver resident HSCs and portal/septal fibroblasts are considered to be the major source of fibrogenic myofibroblasts in the damaged liver and serve as primary targets for anti-fibrotic therapy. Specifically, recent studies on epigenetic myofibroblasts in the damaged liver and serve as primary targets for anti-fibrotic therapy. Specifically, recent studies on epigenetic myofibroblasts in the damaged liver and serve as primary targets for anti-fibrotic therapy. Specifically, recent studies on epigenetic myofibroblasts in the damaged liver and serve as primary targets for anti-fibrotic therapy. Additionally, aHSCs can be manipulated to stop producing collagen and reverse to their quiescent like state. Unfortunately, much less is known about PFS. Although activation of PFS is restricted mostly to cholestatic liver injury, new tools are required to study this population of mesenchymal cells contributing to liver fibrosis.

ACKNOWLEDGMENTS
NIH/NCATS/CTR1 8 KL2 TR000099; NIH/NIDDK 1 R56; DK088837-01A1.

REFERENCES
Abe, R., Donnelly, S. C., Peng, T., Bucala, R., and Metz, C. N. (2001). Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J. Immunol. 166, 7556–7562. doi: 10.4049/jimmunol.166.12.7556
Ashina, K., Sato, H., Yamasaki, C., Katoaka, M., Shiokawa, M., Katayama, S., et al. (2002). Pleiotrophin/heparin-binding growth-associated molecule as a mitogen of rat hepatocytes and its role in regeneration and development of liver. J. Pathol. 196, 2191–2205. doi: 10.1002/jbp.44910(10)61167-4
Ashina, K., Tsai, S. Y., Li, P., Ishii, M., Maxson, R. E. Jr., Sucov, H. M., et al. (2009). Mesenchymal origin of hepatic stellate cells, submesothelial cells, and perivascular mesenchymal cells during mouse liver development. Hepatology 49, 998–1011. doi: 10.1002/hep.22721
Ashina, K., Zhou, B., Pu, W. T., and Tsukamoto, H. (2011). Septum transversum-derived mesothelium gives rise to hepatic stellate cells and perivascular mesenchymal cells in developing mouse liver. Hepatology 53, 983–993. doi: 10.1002/hep.24119
Balgia, S. M., Geschwind, J. G., and Borden, J. (2008). Mesenchymal origin of hepatic stellate cells, submesothelial cells, and perivascular mesenchymal cells in developing mouse liver. Hepatology 53, 983–993. doi: 10.1002/hep.24119
Brinkmann, V., and Zychlinsky, A. (2007). Beneficial suicide: why neutrophils die to make NETs. J. Immunol. 178, 5811–5817. doi: 10.4049/jimmunol.178.11.5811
Buckel, G., and Mattoli, S. (2007). The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. Lab. Invest. 87, 858–870. doi: 10.1038/labinvest.3700654
Berg, T., Rountree, C. B., Lee, L., Estrada, J., Sala, F. G., Choe, A., et al. (2007). Fibroblast growth factor 10 is critical for liver growth during embryogenesis and cancerogenesis. Therefore, it is quite possible that pediatric patients who are born with biliary atresia may retain a rudimentary mechanism by which bile ducts undergoing EMT may account for prominent bile ductular proliferation and fibrogenesis (Deng et al., 2011). Liver sections from patients with biliary atresia were evaluated to detect antigen for the BEG markers 4 and cytokeratin-7 (CK-7), proteins (fibroblast-specific protein 1, also known S100A4; the collagen chaperone heat shock protein 47, HSP47) characteristically expressed by cells undergoing EMT, as well as myofibroblast marker a-smooth muscle actin (a-SMA).

CONCLUSION
The composition of myofibroblasts varies dependent on the etiology of liver fibrosis. Hence, liver resident HSCs and portal/septal fibroblasts are considered to be the major source of fibrogenic myofibroblasts in the damaged liver and serve as primary targets for anti-fibrotic therapy. Specifically, recent studies on epigenetic regulation of hepatic myofibroblasts provide new opportunities for drug discovery (Mann and Mann, 2009; Mann et al., 2010). Furthermore, identification of inactivated phenotype in HSCs suggests that aHSCs can be manipulated to stop producing collagen and reverse to their quiescent like state. Unfortunately, much less is known about PFS. Although activation of PFS is restricted mostly to cholestatic liver injury, new tools are required to study this population of mesenchymal cells contributing to liver fibrosis.
Kisseleva, T., and Brenner, D. A. (2011). Anti-fibrogenic strategies and the
Inokuchi, S., Tsukamoto, H., Park, E., Liu, Z. X., Brenner, D. A., and Seki, E.
(2011). Toll-like receptor 4 mediates alcohol-induced steatohepatitis through
bone marrow-derived and endogenous liver cells in mice. Alcohol. Clin. Exp. Res.
35, 1509–1518.

Iredale, J. P. (2001). The hepatic stellate cell during resolution of liver injury.
Semin. Liver Dis. 21, 427–436. doi: 10.1055/s-2001-715757

Iredale, J., Benvon, R. C., Pickering, J., McCullen, M., Northrop, M., Pasley, S.,
et al. (1998). Mechanisms of spontaneous resolution of rat liver fibrosis. Haptic-
stelle cell apoptosis and reduced hepatic expression of metalloproteinase
inhibitors. J. Clin. Invest. 102, 538–549. doi: 10.1172/JCI10118

Ishida, Y., Kimura, A., Kondo, T., Hayashi, T., Ueno, M., Takakura, N.,
et al. (2007). Essential roles of the CC chemokine ligand 3-CC chemokine
receptor 5 axis in bleomycin-induced pulmonary fibrosis through regulation
of macrophage and fibrocyte infiltration. Am. J. Pathol. 170, 843–854.
doi: 10.1016/j.ajpath.2006.12.013

Ishikawa,S., and Ohtaa, H. (2013). Pathophysiological roles of FGF signaling in the heart.
Front. Physiol. 4:2347. doi: 10.3389/fphys.2013.00247

Iwasaki, K., Brenner, D. A., and Kisseleva, T. (2012). What’s new in liver fibrosis?
Hepatology 56, 332–349. doi: 10.1002/hep.25650

Jaster, R., Lichte, P., Fitzner, B., Brock, P., Glass, A., Karopka, T., et al. (2005).
Peroxisome proliferator-activated receptor gamma overexpression inhibits pro-
fibrogenic activities of immortalised rat pancreatic stellate cells. J. Cell Med. 9,
670–682. doi: 10.1111/j.1582-4934.2005.b00497.x

Jander, M. N., Kruglov, E. A., Lavoe, E. G., Sevigny, J., and Drannoff, J. A. (2005).
Portal fibroblasts regulate the proliferation of bile duct epithelia via expression of
NTFase2. J. Biol. Chem. 280, 22986–22992. doi: 10.1074/jbc.M412371200

Ji, I., Yu, J., Ji, Q., Li, Z., Wang, K., Zhang, J., et al. (2012). Comparative proteomic
analysis of rat hepatic stellate cell activation: a comprehensive view and suppressed
immune response. Hepatology 56, 332–349. doi: 10.1002/hep.25650

Jinnin, M., Ihn, H., Asano, Y., Yamane, K., Trojanowska, M., and Tanaki, K. (2006).
Upregulation of tenasin-C expression by IL-13 in human dermal fibroblasts via the
phosphoinositide 3-kinase/Akt and the protein kinase C signaling pathways.
J. Invest. Dermatol. 126, 551–560. doi: 10.1038/sj.jid.5700900

Kallis, Y. N., and Forbes, S. J. (2009). The bone marrow and liver fibrosis friend or foe?
J. Investig. Med. 119, 1417–1419. doi: 10.1172/JCM39675

Kafuri, R., and Neilson, E. G. (2003). Epithelial-mesenchymal transition and its implications for fibrosis.
J. Clin. Invest. 112, 1776–1784. doi: 10.1172/JCI200320530

Kessenbrock, K., Krumholz, M., Schonemann, U., Back, W., Gross, W. L., Werb,
et al. (2009). Netting neutrophils in autoimmune small-vessel vasculitis. Nat.
Med. 15, 623–625. doi: 10.1038/nm.1959

Kisseleva, T., and Brenner, D. A. (2006). Hepatic stellate cells and the reversal of fibrosis.
J. Gastroenterol. Hepatol. 21(Suppl. 2), S84–S87. doi: 10.1111/j.1440-1746.2006.04584.x

Kisseleva, T., and Brenner, D. A. (2007). Role of hepatic stellate cells in fibrogenesis and the reversal of fibrosis. J. Gastroenterol. Hepatol. 22(Suppl. 1), S73–S78. doi: 10.1111/j.1440-1746.2007.04658.x

Kisseleva, T., and Brenner, D. A. (2008a). Fibrogenesis of parenchymal organs. Proc.
Am. Thorac. Soc. 5, 338–342. doi: 10.1513/pats.200711-161DR

Kisseleva, T., and Brenner, D. A. (2008b). Mechanisms of fibrogenesis. Exp. Biol.
Med. (Maywood). 233, 109–122. doi: 10.1811/0707-MR-190

Kisseleva, T., and Brenner, D. A. (2011). Anti-fibrogenic strategies and the regression of fibrosis. Best Prat. Res. Clin. Gastroenterol. 25, 305–317. doi: 10.1016/j.jpdr.2011.02.011

Kisseleva, T., and Brenner, D. A. (2012). The phenotypic fate and functional role for bone marrow-derived stem cells in liver fibrosis. J. Hepatol. 56, 965–972. doi: 10.1016/j.jhep.2011.09.021
Moore, B. B., Kolodsick, J. E., Thannickal, V. J., Cooke, K., Moore, T. A., Xu et al. Origin of myofibroblasts in liver fibrosis. J. Clin. Invest. 119, 1585–1597. doi: 10.1172/JCI30562

Stefanovic, L., Brenner, D. A., and Stefanovic, B. (2005). Direct hepatotoxic effect of CCL12 in the recruitment of fibrocytes to hepatic stellate cells. J. Biol. Chem. 280, 13952–13961. doi: 10.1074/jbc.M406037200

Quan, T. E., and Buscal, R. (2007). Culture and analysis of circulating fibrocytes. Methods Mol. Med. 135, 423–444. doi: 10.1007/978-1-59745-401-8_28

Quan, T. E., Cowper, S., Wu, S. P., Bockenstedt, L. K., and Buscal, R. (2004). Circulating fibrocytes: collagen-secreting cells of the peripheral blood. Int. J. Biochem. Cell Biol. 36, 598–606. doi: 10.1016/j.biocel.2003.10.005

Reif, S., Lang, A., Lindquist, J. N., Yata, Y., Gabele, E., Scanga, A., et al. (2003). The role of focal adhesion kinase-phosphatidylinositol 3-kinase-akt signaling in hepatic stellate cell proliferation and type I collagen expression. J. Biol. Chem. 278, 8083–8090. doi: 10.1074/jbc.M212922200

Reilkoff, R. A., Buscal, R., and Herzog, E. L. (2011). Fibrocytes: emerging effector cells in chronic inflammation. Nat. Rev. Immunol. 11, 427–435. doi: 10.1038/nri2990

Rinkevich, Y., Mori, T., Sahoo, D., Xu, P. X., Bermingham, J. R. Jr., and Weissman, I. L. (2012). Identification and prospective isolation of a mesothelial precursor lineage giving rise to smooth muscle cells and fibroblasts for mammalian internal organs, and their vasculature. Nat. Cell Biol. 14, 1251–1260. doi: 10.1038/ncb2610

Roderfeld, M., Rath, T., Voswinckel, R., Dierkes, C., Dietrich, H., Zahnert, D., et al. (2009). Bone marrow transplantation demonstrates medullar origin of CD34(+) fibrocytes and ameliorates hepatic fibrosis in Abcb4(−/−). mice. Hepatology 51, 267–276. doi: 10.1002/hep.23274

Russo, F. P., Alison, M. R., Bigger, B. W., Arnofeh, A., Florou, A., Amim, F., et al. (2006). The bone marrow functionally contributes to liver fibrosis. Gastroenterology 130, 1807–1821. doi: 10.1053/j.gastro.2006.01.036

Sahebally, S. M., Burke, J. P., Chang, K. H., Kiernan, M. G., O’Connell, P. R., and Coffey, J. C. (2013). Circulating fibrocytes and Crohn’s disease. Br. J. Surg. 100, 1549–1556. doi: 10.1002/bjs.9302

Sahebally, S. M., Burke, J. P., Chang, K. H., Kiernan, M. G., O’Connell, P. R., and Coffey, J. C. (2013). Circulating fibrocytes and Crohn’s disease. Br. J. Surg. 100, 1549–1556. doi: 10.1002/bjs.9302

Sakai, N., Wada, T., Yokoyama, H., Lipp, M., Ueha, S., Matsushima, K., et al. (2006). Secondary lymphoid tissue chemokine (SLEC/CCL21)/CCR7 signaling regulates fibrocytes in renal fibrosis. Proc. Natl. Acad. Sci. U.S.A. 103, 14098–14103. doi: 10.1073/pnas.0511200103

Scholten, D., Osler-Österreicher, C. H., Scholten, A., Iwaiyako, K., Gu, G., Brenner, D. A., et al. (2010). Genetic labeling does not detect epithelial-to-mesenchymal transition of cholangiocytes in liver fibrosis in mice. Gastroenterology 139, 987–998. doi: 10.1053/j.gastro.2010.05.005

Scholten, D., Reichard, D., Paik, Y. H., Lindert, J., Bhatchayyra, J., Glass, C. K., et al. (2011). Migration of fibrocytes in fibrogenic liver injury. Am. J. Pathol. 179, 189–198. doi: 10.1016/j.ajpath.2011.03.049

Seki, E., De Minics, S., Gwak, G. Y., Kluwe, J., Inokuchi, S., Bursill, C. A., et al. (2009a). CCR1 and CCR5 promote hepatic fibrosis in mice. J. Clin. Invest. 119, 1858–1870.

Seki, E., De Minics, S., Inokuchi, S., Taura, K., Miyai, K., van Rooijen, N., et al. (2009b). CCR2 promotes hepatic fibrosis in mice. Hepatology 50, 185–197. doi: 10.1002/hep.22952

Seki, E., De Minics, S., Osler-Österreicher, C. H., Kluwe, J., Osawa, Y., Brenner, D. A., et al. (2007). TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat. Med. 13, 1324–1332. doi: 10.1038/nm1663

She, H., Xiong, S., Hazra, S., and Tsukamoto, H. (2005). Adipogenic transcriptional regulation of hepatic stellate cells. J. Biol. Chem. 280, 4599–4607. doi: 10.1074/jbc.M107407200

Shimamura, T., Fuziasa, T., Hsuan, B. R., Koi, M., Nakajima, A., and Puric, R. K. (2008). Novel role of IL-13 in fibrosis induced by nonalcoholic steatohepatitis and its amelioration by IL-13-directed cytotoxicity in a rat model. J. Immunol. 181, 4656–4665. doi: 10.4049/jimmunol.181.7.4656

Stefanovic, B., and Brenner, D. A. (2003). 5’-stem-loop of collagen alpha 1(I). mRNA inhibits translation in vitro but is required for triple helical collagen synthesis in vivo. J. Biol. Chem. 278, 927–935. doi: 10.1074/jbc.M209715200

Stefanovic, B., Hellerbrand, C., Holck, M., Briennd, M., Alleibhabber, S., and Brenner, D. A. (1997). Posttranscriptional regulation of collagen alpha1(I) mRNA in hepatic stellate cells. Mol. Cell Biol. 17, 5201–5209.

Stefanovic, B., Lindquist, J., and Brenner, D. A. (2000). The 5’-stem-loop regulates expression of collagen alpha1(I). mRNA in mouse fibroblasts cultured in a three-dimensional matrix. Nucleic Acids Res. 28, 641–647. doi: 10.1093/nar/28.2.641

Stefanovic, B., Schnabl, B., and Brenner, D. A. (2002). Inhibition of collagen alpha 1(I) expression by the 5’-stem-loop as a molecular decoder. J. Biol. Chem. 277, 18229–18237. doi: 10.1074/jbc.M201715200

Stefanovic, B., Brenner, D. A., and Stefanovic, B. (2005). Direct hepatotoxic effect of KC chemokine in the liver without infiltration of neutrophils. Exp. Biol. Med. (Maywood) 230, 573–586.

Strier, R. M., Gomperts, B. N., and Keane, M. P. (2007). The role of CXC chemokines in pulmonary fibrosis. J. Clin. Invest. 117, 549–556. doi: 10.1172/JCI30562

Strier, R. M., Keeley, E. C., Hughes, M. A., Burdick, M. D., and Mehrad, B. (2009). The role of circulating mesenchymal progenitor cells (fibrocytes) in the pathogenesis of pulmonary fibrosis. J. Leukoc. Biol. 86, 1111–1118. doi: 10.1189/jlb.0909132

Suzuki, K., Tanaka, M., Watanabe, N., Saito, S., Nonaka, H., and Miyajima, A. (2008). p75 Neurotrophin receptor is a marker for precursors of stellate cells and portal fibroblasts in mouse fetal liver. Gastroenterology 135, 270–281 e3. doi: 10.1053/j.gastro.2008.03.075

Taura, K., De Minics, S., Seki, E., Hatanan, E., Iwasako, K., Osler-Österreicher, C. H., et al. (2008). Hepatic stellate cells secrete angiopoeitin1 that induces angiogenesis in liver fibrosis. Gastroenterology 135, 1729–1738. doi: 10.1053/j.gastro.2008.03.075

Taura, K., Miura, K., Iwasako, K., Osler-Österreicher, C. H., Kodama, Y., Penz-Osterreicher, M., et al. (2010). Hepatoocytes do not undergo...
epithelial-mesenchymal transition in liver fibrosis in mice. *Hepatology* 51, 1027–1036. doi: 10.1002/hep.23368
Troeger, J. S., Mederacke, I., Gwak, G. Y., Dapito, D. H., Mu, X., Hsu, C. C., et al. (2012). Deactivation of hepatic stellate cells during liver fibrosis resolution in mice. *Gastroenterology* 143, 1073–1083.e22. doi: 10.1053/j.gastro.2012.06.003
Tsukamoto, H. (2005a). Adipogenic phenotype of hepatic stellate cells. *Alcohol. Clin. Exp. Res.* 29, 1325–1335. doi: 10.1097/01.acb.0000189279.92602.fo
Tsukamoto, H. (2005b). Fat paradox in liver disease. *Science* 310, 1350–1352. doi: 10.1126/science.1119325
Tsukamoto, H. (2012). Deactivation of hepatic stellate cells during liver fibrosis resolution in mice. *Hepatology* 55, 1271–1281. doi: 10.1002/hep.24792
Tsukamoto, H., Zhu, N. L., Wang, J., Asahina, K., and Machida, K. (2012). Proliferation and phenotypic modulation of portal fibroblasts by in situ liver perfusion. *J. Vis. Exp.* 64, 3669.
Tsukamoto, H., Zhu, N. L., Asahina, K., Mann, D. A., and Mann, J. (2011). Epigenetic cell fate regulation of hepatic stellate cells. *Hepatol. Res.* 41, 475–482. doi: 10.1111/j.1872-034X.2011.00804.x
Tsukamoto, H., Zhu, N. L., Wang, J., Asahina, K., and Machida, K. (2012). Morphogens and hepatic stellate cell fate regulation in chronic liver disease. *J. Gastroenterol. Hepatol.* 27(Suppl. 2), 94–98. doi: 10.1111/j.1440-1746.2011.07022.x
Tuchweber, B., Desmouliere, A., Bochaton-Piallat, M. L., Rubbia-Brandt, L., and Gabbiani, G. (1996). Proliferation and phenotypic modulation of portal fibroblasts in the early stages of cholestatic fibrosis in the rat. *Lab. Invest.* 74, 265–278.
Uchinami, H., Seki, E., Brenner, D. A., and D’Armiento, J. (2006). Loss of MMP 13 attenuates murine hepatic injury and fibrosis during cholestasis. *Hepatology* 44, 420–429. doi: 10.1002/hep.21268
Uchio, K., Tuchweber, B., Manabe, N., Gabbiani, G., Rosenbaum, J., and Desmouliere, A. (2002). Cellular retinol-binding protein-1 expression and modulation during in vivo and in vitro myofibroblastic differentiation of rat hepatic stellate cells and portal fibroblasts. *Lab. Invest.* 82, 619–628. doi: 10.1038/labinvest.3780456
Venkataraman, G., Raman, R., Sasisekharan, V., and Sasisekharan, R. (1999). Molecular characteristics of fibroblasts growth factor-fibroblast growth factor receptor-heparin-like glycosaminoglycan complex. *Proc. Natl. Acad. Sci. U.S.A.* 96, 3656–3663. doi: 10.1073/pnas.96.7.3658
von Kockritz-Blickwede, M., Goldmann, O., Thulin, P., Heinemann, K., Norrby-Stewe, M., Landfester, K., et al. (2008). Phagocytosis-independent antimicrobial activity of mast cells by means of extracellular trap formation. *Blood* 111, 3070–3080. doi: 10.1182/blood-2007-10-104018
Wada, T., Sakai, N., Matsushima, K., and Kaneko, S. (2007). Fibrocytes: a new insight into kidney fibrosis. *Kidney Int.* 72, 269–273. doi: 10.1038/sj.ki.5002525
Watsky, M. A., Weber, K. T., Sun, Y., and Postlethwaite, A. (2010). New insights into the mechanism of fibroblast to myofibroblaste transformation and associated pathologies. *Int. Rev. Cell Mol. Biol.* 282, 165–192. doi: 10.1016/S1937-6448(10)82004-0
Wells, R. G. (2008). The role of matrix stiffness in regulating cell behavior. *Hepatology* 47, 1394–400. doi: 10.1002/hep.22193
Wells, R. G. (2014). The portal fibroblast: not just a poor man’s stellate cell. *Gastroenterology* 147, 41–47. doi: 10.1053/j.gastro.2014.05.001
Wells, R. G., Kruglov, E., and Dranoff, J. A. (2004). Autocrine release of TGF-beta by portal fibroblasts regulates cell growth. *FEBS Lett.* 559, 107–110. doi: 10.1016/S0014-5793(04)00037-7
Wen, J. W., Olsen, A. L., Perepelyuk, M., and Wells, R. G. (2012). Isolation of rat portal fibroblasts by in situ liver perfusion. *J. Vis. Exp.* 64, 3669.
Yang, L., Jung, Y., Omenetti, A., Witek, R. P., Choi, S., Vandongen, H. M., et al. (2008). Fate-mapping evidence that hepatic stellate cells are epithelial progenitors in adult mouse livers. *Stem Cells* 26, 2104–2113. doi: 10.1634/stemcells.2008-0115
Yang, M. D., Chiang, Y. M., Higashiyama, R., Asahina, K., Mann, D. A., Mann, J., et al. (2012). Rosmarinic acid and baicalin epigenetically derepress peroxisomal proliferator-activated receptor gamma in hepatic stellate cells for their antifibrotic effect. *Hepatology* 55, 1271–1281. doi: 10.1002/hep.24792
Yata, Y., Scanga, A., Gillan, A., Yang, L., Reif, S., Breindl, M., et al. (2003). DNase I-hypersensitive sites enhance alpha1(I). collagen gene expression in hepatic stellate cells. *Hepatology* 37, 267–76. doi: 10.1053/jhep.2003.50067
Yousefi, S., Gold, J. A., Andina, N., Lee, J. J., Kelly, A. M., Kozlowski, E., et al. (2008). Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense. *Nat. Med.* 14, 949–953. doi: 10.1038/nm.1855
Yovchev, M. I., Zhang, J., Neufeld, D. S., Grozdanov, P. N., and Dabeva, M. D. (2009). Thymus cell antigen-1-expressing cells in the oval cell compartment. *Hepatology* 50, 601–611. doi: 10.1002/hep.23012

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 01 April 2014; accepted: 25 June 2014; published online: 22 July 2014.

Citation: Xu J, Liu X, Koyama Y, Wang P, Lan T, Kim I-G, Kim IH, Ma H-Y and Kisseleva T (2014) The types of hepatic myofibroblasts contributing to liver fibrosis of different etiologies. Front. Pharmacol. 5:167. doi: 10.3389/fphar.2014.00167

This article was submitted to Inflammation Pharmacology, a section of the journal Frontiers in Pharmacology.

Copyright © 2014 Xu, Liu, Koyama, Wang, Lan, Kim, Kim, Ma and Kisseleva. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.